About a year norfloxacin tinidazole wikipedia "I have聽worked with NKTR-181 since this new molecule entered the clinic, and I believe that NKTR-181聽could聽be an important advance in analgesia,聽maybe聽even a breakthrough," said Dr. Lynn Webster,聽the chief medical director of CRI Lifetree. "Although this Phase II study did not achieve its primary endpoint, this is not uncommon in opioid development.聽 What is important is that the large majority of patients in this trial were聽able to achieve meaningful and long-lasting pain relief from NKTR-181. Providing analgesia without the pronounced CNS effects and euphoria of standard opioids is the future of analgesic development."
|